Intravenous immunoglobulin in recurrent-relapsing inflammatory optic neuropathy

Area of Science:

• Neuro-ophthalmology
• Immunology
• Autoimmune diseases

Background:

• Recurrent-relapsing inflammatory optic neuropathies can lead to severe vision loss.
• Long-term corticosteroid use preserves vision but often causes significant side effects.
• Alternative treatments are needed for steroid-dependent cases.

Purpose of the Study:

• To evaluate the efficacy of intravenous immunoglobulins (IVIg) in managing steroid-responsive recurrent-relapsing optic neuropathies.
• To assess IVIg as a steroid-sparing agent in this patient population.

Main Methods:

• A semi-prospective case series involving 6 patients across 4 medical centers.
• Patients had steroid-responsive recurrent-relapsing optic neuropathy.
• Outcomes measured included visual status, remission rates, duration of corticosteroid use, and adverse events.

Main Results:

• Vision stabilized in all 6 patients treated with IVIg, with no improvement or worsening.
• Five out of six patients were able to discontinue corticosteroids after IVIg treatment.
• One patient experienced an adverse event during IVIg infusion; two patients had late relapses on IVIg.

Conclusions:

• Intravenous immunoglobulin (IVIg) is an effective steroid-sparing treatment for selected patients with steroid-dependent recurrent-relapsing autoimmune optic neuropathy.
• IVIg can help maintain stable vision and reduce reliance on long-term corticosteroids.